TY - JOUR
T1 - Recurrence Risk Based on Pathologic Stage After Neoadjuvant Chemoradiotherapy in Esophageal Squamous Cell Carcinoma
T2 - Implications for Risk-Based Postoperative Surveillance Strategies
AU - Zhou, Sha
AU - Liu, Shiliang
AU - Zhang, Li
AU - Guo, Suping
AU - Shen, Jingxian
AU - Li, Qiaoqiao
AU - Yang, Hong
AU - Feng, Yanfen
AU - Liu, Mengzhong
AU - Lin, Steven H.
AU - Xi, Mian
N1 - Funding Information:
DISCLOSURE Steven H. Lin has received research funding from STCube Pharmaceuticals, Peregrine Pharmaceuticals, Hitachi Chemical Diagnostics, and Roche/Genentech, is on the advisory board for AstraZeneca, and has received honoraria from US Oncology and ProCure. The other authors have no conflicts of interest to declare.
Funding Information:
ACKNOWLEDGMENT This work was supported by Grants from the Natural Science Foundation of Guangdong Province (2015A030310044), the Science and Technology Planning Project of Guangdong Province (2013B021800156), and the Guangdong Esophageal Cancer Institute Science and Technology Program (M201715).
Publisher Copyright:
© 2018, Society of Surgical Oncology.
Copyright:
Copyright 2019 Elsevier B.V., All rights reserved.
PY - 2018/11/1
Y1 - 2018/11/1
N2 - Background: This study aimed to investigate the association between pathologic stage and recurrence risk and survival for patients with esophageal squamous cell carcinoma (SCC) after neoadjuvant chemoradiotherapy (CRT). Methods: This retrospective analysis consisted of two patient cohorts who had esophageal SCC treated with neoadjuvant CRT and esophagectomy at two major academic institutions between 2002 and 2015. The study included 174 patients in the training cohort and 51 patients in the validation cohort. Recurrence pattern, frequency, and survival according to pathologic stage were analyzed. Results: After surgery, patients in the training cohort had the following pathologic categories: stage 0 (44.8%, n = 78), stage 1 (6.9%, n = 12), stage 2 (35.6%, n = 62), and stage 3 (12.6%, n = 22). During a median follow-up period of 53.9 months, recurrences developed in 59 patients. The recurrence rates were 22.2% for stages 0 and 1, 38.7% for stage 2, and 68.2% for stage 3 (stages 0 and 1 vs. stage 2 [P = 0.028], stages 0 and 1 vs. stage 3 [P < 0.001], and stage 2 vs. stage 3 [P = 0.017]). More than 20% of patients with stages 0 and 1 or 2 disease experienced late relapses after 3 years of follow-up evaluation, whereas all the patients with pathologic stage 3 had recurrences within 2 years. The 5-year recurrence-free survival rate was 74.7% for the patients with pathologic stage 0 or 1, 61.4% for those with stage 2, and 20.9% for those with stage 3 disease (P < 0.001). These major findings were successfully reproduced in the Western validation cohort. Conclusions: Patients with a higher pathologic stage were associated with a significantly higher risk of recurrences and worse survival. Multicenter and prospective validation is warranted.
AB - Background: This study aimed to investigate the association between pathologic stage and recurrence risk and survival for patients with esophageal squamous cell carcinoma (SCC) after neoadjuvant chemoradiotherapy (CRT). Methods: This retrospective analysis consisted of two patient cohorts who had esophageal SCC treated with neoadjuvant CRT and esophagectomy at two major academic institutions between 2002 and 2015. The study included 174 patients in the training cohort and 51 patients in the validation cohort. Recurrence pattern, frequency, and survival according to pathologic stage were analyzed. Results: After surgery, patients in the training cohort had the following pathologic categories: stage 0 (44.8%, n = 78), stage 1 (6.9%, n = 12), stage 2 (35.6%, n = 62), and stage 3 (12.6%, n = 22). During a median follow-up period of 53.9 months, recurrences developed in 59 patients. The recurrence rates were 22.2% for stages 0 and 1, 38.7% for stage 2, and 68.2% for stage 3 (stages 0 and 1 vs. stage 2 [P = 0.028], stages 0 and 1 vs. stage 3 [P < 0.001], and stage 2 vs. stage 3 [P = 0.017]). More than 20% of patients with stages 0 and 1 or 2 disease experienced late relapses after 3 years of follow-up evaluation, whereas all the patients with pathologic stage 3 had recurrences within 2 years. The 5-year recurrence-free survival rate was 74.7% for the patients with pathologic stage 0 or 1, 61.4% for those with stage 2, and 20.9% for those with stage 3 disease (P < 0.001). These major findings were successfully reproduced in the Western validation cohort. Conclusions: Patients with a higher pathologic stage were associated with a significantly higher risk of recurrences and worse survival. Multicenter and prospective validation is warranted.
UR - http://www.scopus.com/inward/record.url?scp=85053482400&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85053482400&partnerID=8YFLogxK
U2 - 10.1245/s10434-018-6736-7
DO - 10.1245/s10434-018-6736-7
M3 - Article
C2 - 30194608
AN - SCOPUS:85053482400
SN - 1068-9265
VL - 25
SP - 3639
EP - 3646
JO - Annals of surgical oncology
JF - Annals of surgical oncology
IS - 12
ER -